Investment
Features
FeesSafety
Academy
More
Pluang+

Compare State Street SPDR Bloomberg High Yield Bond ETF (JNK) vs Smith & Nephew plc (SNN) Price & Performance

State Street SPDR Bloomberg High Yield Bond ETFTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

State Street SPDR Bloomberg High Yield Bond ETF vs Smith & Nephew plc — how do they compare? State Street SPDR Bloomberg High Yield Bond ETF trades at $92.72 (market cap $5.86B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Smith & Nephew plc is the larger of the two by market cap, and Smith & Nephew plc pays a 2.95% dividend while State Street SPDR Bloomberg High Yield Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg High Yield Bond ETF for 61 Days and Smith & Nephew plc for 121 Days on average.

JNKSNN
Market Cap
$5.86B$11.10B
Volume
7,780,0021,051,703
Sector
Fixed IncomeHealth
52-Week High
$98.02$37.17
52-Week Low
$92.30$26.42
Typical Hold Time
61 Days121 Days
Enterprise Value
—$14.13B
Dividend Yield
—2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

State Street SPDR Bloomberg High Yield Bond ETF

JNK, a high-yield bond ETF, trades at $92.83, up 0.08% on the day, amid a bearish technical signal from moving averages. The fund maintains a consistent dividend payout, with recent distributions of $0.53. Market sentiment is influenced by rising bond yields and geopolitical tensions, as highlighted in recent financial news.

The outlook for JNK is challenged by high interest rates and inflation concerns, which pressure junk bond valuations. Opportunities exist for income-focused investors due to the ETF's yield, but risks include further yield spikes and economic slowdowns affecting credit quality.

Smith & Nephew plc

Smith+Nephew (SNN) trades at $27.24, near its 52-week low of $27.05, with a bearish technical signal despite recent earnings beats. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%, but the stock faces headwinds from analyst downgrades and CFO departure news. Product launches like the EVOS PELVIC System highlight innovation, yet investor sentiment remains cautious.

The outlook is mixed: strong fundamentals and undervaluation (P/E 18.34) offer upside, but technical weakness and competitive risks temper near-term gains. Key risks include execution challenges and market volatility, while institutional interest (e.g., BlackRock's $505M stake) provides support. Investors should weigh solid profitability against sentiment-driven price pressure.

Returns comparison

Trailing returns across standard periods

About State Street SPDR Bloomberg High Yield Bond ETF

JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.

Read more on JNK →

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN →